Park Hosub, Jee Seungyun, Son Hwangkyu, Cha Hyebin, Bang Seongsik, Kim Hyunsung, Shin Su-Jin, Cha Chihwan, Chung Min Sung, Myung Jaekyung, Paik Seung Sam
Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Korea.
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea.
Diagnostics (Basel). 2022 Feb 14;12(2):487. doi: 10.3390/diagnostics12020487.
Single-stranded DNA binding protein 2 () is involved in the DNA damage response and the maintenance of genome stability. Previous studies have suggested that has a tumor suppressor function or oncogenic function. Loss of expression has been reported in various tumors. However, the role of expression in invasive breast carcinoma has not been reported.
Immunohistochemical staining for was performed on tissue microarrays consisting of 491 invasive breast carcinoma cases. The result of nuclear staining was stratified as either negative or positive. Then, we investigated the correlations between expression and various clinicopathological parameters and patient outcomes.
Loss of nuclear expression was observed in 61 cases (12.4%) of 491 invasive breast carcinomas. Loss of nuclear expression was significantly correlated with larger tumor size ( < 0.001, chi-squared test), higher histological grade ( = 0.016, Cochran-Armitage trend test), higher pathological T stage ( < 0.001, Cochran-Armitage trend test), estrogen receptor status ( < 0.001, chi-squared test), and molecular subtype ( < 0.001, chi-squared test). Kaplan-Meier survival analysis revealed that patients with loss of nuclear expression had worse overall survival ( = 0.013, log-rank test). However, loss of nuclear expression was not correlated with recurrence-free survival ( = 0.175, log-rank test).
Loss of nuclear expression was associated with adverse clinicopathological characteristics and poor patient outcomes. acts as a tumor suppressor in invasive breast carcinoma and may be used as a prognostic biomarker.
单链DNA结合蛋白2（）参与DNA损伤反应和基因组稳定性的维持。先前的研究表明，具有肿瘤抑制功能或致癌功能。在各种肿瘤中均有报道表达缺失。然而，表达在浸润性乳腺癌中的作用尚未见报道。
对由491例浸润性乳腺癌病例组成的组织芯片进行免疫组织化学染色。细胞核染色结果分为阴性或阳性。然后，我们研究了表达与各种临床病理参数和患者预后之间的相关性。
在491例浸润性乳腺癌中，有61例（12.4%）观察到细胞核表达缺失。细胞核表达缺失与肿瘤较大（<0.001，卡方检验）、组织学分级较高（=0.016， Cochr an-Armitage趋势检验）、病理T分期较高（<0.001， Cochr an-Armitage趋势检验）、雌激素受体状态（<0.001，卡方检验）和分子亚型（<0.001，卡方检验）显著相关。Kaplan-Meier生存分析显示，细胞核表达缺失的患者总生存期较差（=0.013，对数秩检验）。然而，细胞核表达缺失与无复发生存期无关（=0.175，对数秩检验）。
细胞核表达缺失与不良的临床病理特征和患者预后不良相关。在浸润性乳腺癌中起肿瘤抑制作用，可作为一种预后生物标志物。
